OUR
JOURNEY

July

Research Breakthrough: "Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas" (Nature Genetics)

August

Research Breakthrough: "Genetic landscape of esophageal squamous cell carcinoma" (Nature Genetics)

January

Genetron Health Launches Oncology Diagnostics and Monitoring Platform

February

Research Breakthrough: "Recurrent gain-of-function USP8 mutations in Cushing's disease" (Cell Research)

September

Research Breakthrough: "The genome-wide mutational landscape of pituitary adenomas" (Cell Research)

October

Biochip reader GENETRON 3D is approved for the China market

December

HUMAN IDH1 Gene Mutation Test is approved for the China market

HUAMN TERT Gene Mutation Test is approved for the China market

January

Genetron Health Launches Biopharma Services Platform

May

Research Breakthrough: "The genomic landscape of TERT promoter wildtype-IDH wildtype glioblast" (Nature Communications)

August

Research Breakthrough: "Identification of recurrent USP48 and BRAF mutations in Cushing's disease" (Nature Communications)

Research Breakthrough: "Biological Role and Therapeutic Potential of IDH Mutations in Cancer" (Cancer Cell)

November

Research Breakthrough: "Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNA" (Acta Neuropathologica)

January

Genetron Health Launches Early Cancer Screening Platform

March

Prospective cohort study for early stage liver cancer: "Screening of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy" (PNAS)

April

Genetron Health's core technology "One-Step Seq Method" receives IP patent in China

November

NGS Platform GENETRON S5 is approved to go to market in China

Auto sample loading system GENETRON Chef is approved to go to market in China

Genetron joins hands with iKang Group to create a new chapter in the prevention and treatment of liver cancer

January

Gene sequencer GENETRON S2000 is approved to go to market in China

8-gene Lung Cancer Assay is approved to go to market in China

March

Contributes to China's first 'NGS Clinical Application Standards'

June

Research Breakthrough: For the first time, Genetron Health reported DNA methylation data, distinct clusters termed H3-Pons, H3-Medulla, IDH, and PA-like, each associated with unique genomic and clinical profiles. Clinical data shows significant different overall survival between these clusters and pathway analysis demonstrates different oncogenic mechanisms in these samples. (Nature Communications)

JUNE

Listed on Nasdaq

August

Genetron Health becomes the only company to participate in China's Early Cancer National R&D Projects covering three different cancer varieties (liver, lung, digestive tract)

September

Genetron Health receives U.S. FDA Breakthrough Device designation for its blood-based NGS test, HCCscreen

November

Joined the "Liver Cancer Early Screening Comprehensive Prevention" public health initiative

December

Genetron Health establishes various partnerships with AstraZeneca, Bayer, CStone Pharma, Novartis, and others

January

Genetron Health begins strategic partnership with Chia Tai Tianqing (CTTQ) Pharmaceutical Group

March

Genetron Health releases new prospective cohort study data of HCCscreen for early liver cancer screening

July

Genetron Health receives CE Mark for 8-Gene Lung Cancer Assay

August

Genetron Health receives full marks under the NCCL external quality assessment of NGS-based comprehensive genomic profiling for solid tumors, ranking first among the 63 laboratories nationwide

November

Genetron Health’s early precision lung cancer diagnosis and treatment project, a joint initiative with the West China Hospital of Sichuan University, won the second prize of China’s National Science and Technology Progress Award

Genetron Health signed a collaboration agreement with AstraZeneca R&D China for the joint development in China of NGS-based tumor-informed (personalized) MRD tests for various solid tumor types

Genetron Health’s liver cancer screening results and technology findings are included in the expert consensus on the role of hematological markers in the early clinical screening of hepatocellular carcinoma – submitted by the Infectious Disease Prevention and Control Division of the Chinese Preventive Medicine Association.

Genetron Health's multi-gene mutation detection kit Onco PanScan obtains CE Mark

February

Genetron Health announces companion diagnostic collaboration agreement with HUTCHMED's ORPATHYS® for NSCLC

Genetron Health's proprietary Mutation Capsule technology was granted an invention patent (201910983038.8) by the China National Intellectual Property Administration

March

Genetron Health's Beijing clinical laboratory became the only laboratory nationwide to receive full marks in the NCCL EQA pre-research project of bioinformatics analysis on tumor mutation burden testing with dual sequencing platforms

Genetron Health's latest technological advances in precision oncology were highlighted in the Nature Index 2022 Big 5 Science Nations

April

Genetron Health Receives CE Mark for Human B Lymphocyte Minimal Residual Disease Detection Kit Seq-MRD^®

June

Genetron Health receives CE Mark for its FusionScan Plus Kit for human multi-genes

Genetron Health receives CAP Accreditation for its Maryland Laboratory

August

Genetron Health's early liver cancer screening technology was incorporated into the China Guideline for Liver Cancer Screening (2022, Beijing)

November

Genetron Health signed contracts with AstraZeneca and Roche respectively to each build a precision oncology ecosystem

Two new liquid biopsy products, GENETRON MRD and Onco Sonar, were launched during the Annual Meeting of the Chinese Society of Clinical Oncology

December

A research paper based on Genetron Health's early cancer screening technology, Mutation Capsule Plus, was published by Science Translational Medicine

March

Participated in the formulation of General technical requirements for BRCA mutation detection kit and database (High-throughput sequencing)

July

Participated in the compilation of The Classification Criteria of High Through-put Gene Sequencing Projects

August

Exclusively participated in the performance confirmation study of NGS-based comprehensive genomic profiling product initiated by the NCCL and published results in the American Journal of Clinical Pathology

September

Approval of PDGFRA D842V Mutation Detection Kit in China as the companion diagnostic kit of Avapritinib®

November

Launch of the personalized MRD test for solid tumors in exclusive collaboration with AstraZeneca R&D China

March

Genetron Health finalized its privatization process and voluntarily delisted from NASDAQ

April

Research achievements in liver cancer early screening was incorporated into the National Health Commission's Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2024 Edition)

May

Collaborated with the National Center for Neurological Disorders (Huashan Hospital) to commercialize innovative technologies for the precision diagnosis of brain tumors

Joined the first "Full-Chain Innovation Cooperation Alliance for Precision Medicine and Biopharmaceutical Industry" in the Yangtze River Delta region

Beijing Genetron Medical Laboratory was recognized as "Beijing specialized and sophisticated small and medium-sized enterprises (SMEs)"

December

Partnered with the West China Hospital of Sichuan University, responsible for the "Precision Molecular Diagnosis" direction under the National Industrial Innovation Center of Precision Medicine for Precision Medicine Industry, being one of the first selected enterprises

Signed a "Collaborative Talent Development Strategic Cooperation Agreement" with the Institute of Basic Medical Sciences (IBMS) of the Chinese Academy of Medical Sciences (CAMS) and the School of Basic Medicine (SBM) of Peking Union Medical College (PUMC)

Strategic cooperation with Changzhou Xitaihu Institute for Frontier Technology of Cell Therapy

February

Passes CFDI Inspection, Aids in the Approval and Launch of China's First PD-1 Monoclonal Antibody for Head and Neck Squamous Cell Carcinoma

Participates in Formulating China's First National Standard for Quality Control of High-Throughput Human Gene Sequencing Data, Facilitating the Establishment of Authoritative Standards for Whole-Genome Sequencing Data

March

Ranks as Chain Leader of Wuxi's Precision Medicine and Smart Healthcare Industry Chain

May

Participates in "National Key Science and Technology Special Projects‌", Leading R&D and Clinical Application of Liquid Biopsy and Big Data Technologies for Solid Tumors

Aids in Successful Approval of New Indication for HANSON PHARMA's Lung Cancer Targeted Drug Almonertinib®